NasdaqCM:DMRABiotechs
Will Widening Net Losses And New Finance Chief Change Damora Therapeutics' (DMRA) Narrative
Damora Therapeutics, Inc. recently reported first-quarter 2026 results, with a net loss of US$27.78 million versus US$2.53 million a year earlier, while basic and diluted loss per share from continuing operations narrowed to US$0.62 from US$1.92.
Ahead of this earnings release, the company also reshaped its finance leadership, appointing experienced finance executive and CPA Brian Burkavage as principal financial and accounting officer effective May 1, 2026.
We’ll now examine how the sharply...